Apogee has reported initial data on its long-acting eczema drug, which appears to have shown promise in inducing relief. The company's progress with the drug has drawn significant interest, with reports indicating that AbbVie is acquiring Apogee in a deal worth around $11 billion. The drug is expected to move into phase 3 testing, although details of the acquisition and the drug's development timeline are not fully clear.